A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable...
show moreAuthor | cancerGRACE |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
Browse Spreaker Catalogue to discover great new content
Browse Spreaker Catalogue to discover great new content
It's so quiet here...
Time to discover new episodes!